Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

Claims 1-15 (canceled)

Claim 16. (currently amended): A method for monitoring the clinical effectiveness of the administration of a formulation comprising one or more therapeutic growth factor proteins in the treatment of coronary artery disease, the method comprising the steps of :

a. selecting a patient displaying symptoms of coronary artery disease;
b. administering at least one dose of an effective amount of a first therapeutic growth factor protein formulation comprising a growth factor protein selected from the group consisting of FGF-1, FGF-2, ~~PlGF~~VEGF-B, and mixtures thereof by inhalation therapy;
c. obtaining a sample of a biological fluid from the patient displaying symptoms of coronary artery disease;
d. performing an assay of the biological fluid to determine an amount of CPK-MB present in the fluid;
e. determining, based on monitoring the amount of CPK-MB present in the fluid, whether an additional dose of a therapeutic growth factor protein formulation is necessary;
f. depending on the results of the step e), administering one or more additional doses of a second growth factor protein formulation comprising a growth factor protein being selected from the group consisting of FGF-1, FGF-2, ~~PlGF~~VEGF-B, and mixtures thereof; and
g. repeating steps c) through f) until the assayed levels of CPK-MB in the biological fluid indicates the clinical effectiveness of the administration of the

pharmaceutical formulation and amelioration of the symptoms of coronary artery disease in the patient, or until there is a contraindication to continued treatment.

Claim 17. (canceled)

Claim 18. (canceled)

Claim 19. (canceled)

Claim 20. (previously presented): The method of claim 16 wherein the growth factor protein formulation is a dry powder formulation.

Claim 21. (previously presented): The method of claim 16 wherein the growth factor protein formulation is a liquid aerosol formulation.

Claim 22. (previously presented): The method of claim 16, wherein the symptoms of coronary artery disease are brought on by a condition selected from the group consisting of myocardial infarct, unstable angina, an acute anginal attack and reperfusion injury.

Claim 23. (previously presented): The method of claim 22, wherein the reperfusion injury is induced by a procedure selected from the group consisting of thrombolytic therapy, bypass surgery and angioplasty.

Claim 24. (currently amended): A method for monitoring the clinical effectiveness of the administration of a potentially therapeutic pharmaceutical formulation selected from the group consisting of FGF-1, FGF-2, ~~PIGF~~VEGF-B, and mixtures thereof, in the treatment of chronic coronary artery disease, the method comprising the steps of:

a. selecting a patient displaying symptoms of chronic coronary artery disease;
b. administering at least one dose of an effective amount of a first therapeutic growth factor protein formulation comprising a growth factor protein selected

from the group consisting of FGF-1, FGF-2, ~~PIGF~~VEGF-B, and mixtures thereof by inhalation therapy;

~~e.obtaining a sample of a biological fluid from the patient displaying symptoms of chronic coronary artery disease;~~

~~d.~~c. ~~performing an assay of the biological fluid to determine an amount of CPK-MB present in the fluid~~monitoring one or more clinical indicators of chronic coronary artery disease;

~~e.~~d. determining, based on monitoring the ~~amount of CPK-MB present in the fluid~~one or more clinical indicators of chronic coronary artery disease, whether an additional dose of a therapeutic growth factor protein formulation is necessary;

~~f.~~e. depending on the results of the step e), administering one or more additional doses of a second growth factor protein formulation comprising a growth factor protein being selected from the group consisting of FGF-1, FGF-2, ~~PIGF~~VEGF-B, and mixtures thereof; and

~~g.~~f. repeating steps c) through f) until ~~the assayed levels of CPK-MB in the biological fluid indicates the clinical effectiveness of the administration of the pharmaceutical formulation and~~there is a clinical indication of amelioration of the symptoms of chronic coronary artery disease in the patient, or until there is a contraindication to continued treatment.

Claim 25. (canceled)

Claim 26. (canceled)

Claim 27. (previously presented): The method of claim 24 wherein the growth factor protein formulation is a dry powder formulation.

Claim 28. (previously presented): The method of claim 24 wherein the growth factor protein formulation is a liquid aerosol formulation.

Claims 29-35. (canceled)